ABSTRACT
A sex paradox is seen in pulmonary arterial hypertension (PAH) whereby female sex is a risk factor for development of the disease but male sex is often associated with poorer outcomes. Although data are limited regarding the potential molecular mechanisms underlying sex-specific variations in PAH including its various subtypes, there is emerging evidence regarding the potential role of sex differences in pathways governing the balance between underlying inflammatory and vasoactive mechanisms. Chronic thromboembolic pulmonary hypertension (CTEPH) is a subtype of pulmonary hypertension that is classically characterized as a procoagulant state and yet also involving some degree of proinflammatory activity. Therefore, we sought to determine whether eicosanoid mediators, endogenous lipid signaling molecules that have been implicated in a range of inflammatory and vasoactive responses, vary by sex in patients with CTEPH. We studied 287 patients (43.5% female) with confirmed CTEPH from a single center and assayed plasma samples using liquid chromatography – mass spectrometry to profile 500 eicosanoid analytes. We found significant sex-specific variations in eicosanoid profiles after adjusting for age and BMI, with males demonstrating a predominance of inflammatory-pathway related eicosanoids. Sex-specific variation in eicosanoid pathway related mechanisms may underlie sexual dimorphism in CTEPH outcomes.
Competing Interest Statement
None of the authors have any potential conflicts of interest relative to the study. NHK has served as consultant for Bayer, Janssen, Merck, United Therapeutics and has received lecture fees for Bayer, Janssen. NHK has received research support from Acceleron, Eiger, Gossamer Bio, Lung Biotechnology, SoniVie. A.M.B. served as a consultant to Biogen.
Funding Statement
This work was supported in part by National Institutes of Health (NIH) grants S10OD020025, R01ES027595, K01DK116917, R01HL131532, R01HL151828, U54AG065141, and a pulmonary hypertension PHAB award from Bayer.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of California San Diego gave ethical approval of this work and all patients signed informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Requests for de-identified data may be directed to the corresponding authors (MJ, SC) and will be reviewed by the Office of Research Administration at UCSD prior to issuance of data sharing agreements. Data limitations are designed to ensure patient and participant confidentiality.
Non-standard Abbreviations and Acronyms
- BMI
- Body mass index
- CTEPH
- Chronic thromboembolic pulmonary hypertension
- PAH
- Pulmonary arterial hypertension
- LC-MS
- Liquid chromatography - mass spectrometry
- mRAP
- Mean right atrial pressure
- PAH
- Pulmonary arterial hypertension
- PVR
- Pulmonary vascular resistance
- RHC
- Right heart catheterization
- 6MWD
- 6-minute walk distance
